Chi-Med present pre-clinical data at AACR

Hutchison China MediTech presented pre-clinical data for fruquintinib and sulfatinib at the American Association for Cancer Research annual meeting in Washington DC on 1-5 April.

Fruquintinib and sulfatinib are both being evaluated in phase III clinical trials for various cancers.

Story provided by StockMarketWire.com